Decision ruleHaematology
International Staging System for multiple myeloma (ISS)
Stages multiple myeloma into three stages using serum β2-microglobulin and albumin.
Updated 31 October 2026
When to use it
Patients with newly diagnosed symptomatic multiple myeloma, before treatment.
What it needs
- Serum β2-microglobulin
- Serum albumin
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 1 | Stage I: median survival ≈ 62 months |
| 2 | Stage II: median survival ≈ 44 months |
| ≥ 3 | Stage III: median survival ≈ 29 months |
Practical tip
β2-microglobulin rises with renal impairment, so stage III mixes tumour burden and kidney damage.
2 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
